Gevers TJG - Search Results

1

Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months.

Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, Taubert R, Jaeckel E, Manns MP, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener DJN, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse AW, Drenth JPH, Heneghan MA. Pape S, et al. Among authors: gevers tjg. Clin Gastroenterol Hepatol. 2020 Jun;18(7):1609-1617.e4. doi: 10.1016/j.cgh.2019.11.013. Epub 2019 Nov 9. Clin Gastroenterol Hepatol. 2020. PMID: 31715274

2

Somatostatin analogues for treatment of polycystic liver disease.

Gevers TJ, Drenth JP. Gevers TJ, et al. Curr Opin Gastroenterol. 2011 May;27(3):294-300. doi: 10.1097/MOG.0b013e328343433f. Curr Opin Gastroenterol. 2011. PMID: 21191289 Review.

3

Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review.

Gevers TJ, Slavenburg S, van Oijen MG, Drenth JP. Gevers TJ, et al. Neth J Med. 2011 May;69(5):216-21. Neth J Med. 2011. PMID: 21646668 Free article. Review.

4

Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum.

van Gulick JJ, Gevers TJ, van Keimpema L, Drenth JP. van Gulick JJ, et al. Neth J Med. 2011 Sep;69(9):367-71. Neth J Med. 2011. PMID: 21978978 Free article. Review.

5

Low prevalence of cardiac valve abnormalities in patients with autosomal dominant polycystic liver disease.

Gevers TJ, de Koning DB, van Dijk AP, Drenth JP. Gevers TJ, et al. Liver Int. 2012 Apr;32(4):690-2. doi: 10.1111/j.1478-3231.2011.02683.x. Epub 2011 Nov 14. Liver Int. 2012. PMID: 22099398 No abstract available.

6

The long-term outcome of patients with polycystic liver disease treated with lanreotide.

Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, Hoffmann AL, Dekker HM, de Man RA, van Keimpema L, Drenth JP. Chrispijn M, et al. Aliment Pharmacol Ther. 2012 Jan;35(2):266-74. doi: 10.1111/j.1365-2036.2011.04923.x. Epub 2011 Nov 24. Aliment Pharmacol Ther. 2012. PMID: 22111942 Clinical Trial.

7

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.

Gevers TJ, Chrispijn M, Wetzels JF, Drenth JP. Gevers TJ, et al. BMC Nephrol. 2012 Apr 4;13:17. doi: 10.1186/1471-2369-13-17. BMC Nephrol. 2012. PMID: 22475206 Free PMC article. Clinical Trial.

8

Diagnosis and management of polycystic liver disease.

Gevers TJ, Drenth JP. Gevers TJ, et al. Nat Rev Gastroenterol Hepatol. 2013 Feb;10(2):101-8. doi: 10.1038/nrgastro.2012.254. Epub 2013 Jan 8. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23296249 Review.

9

Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.

Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP. Chrispijn M, et al. J Hepatol. 2013 Jul;59(1):153-9. doi: 10.1016/j.jhep.2013.03.004. Epub 2013 Mar 14. J Hepatol. 2013. PMID: 23499726 Clinical Trial.

10

Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.

Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, Nevens F, Drenth JP. Gevers TJ, et al. Gastroenterology. 2013 Aug;145(2):357-65.e1-2. doi: 10.1053/j.gastro.2013.04.055. Epub 2013 May 7. Gastroenterology. 2013. PMID: 23665274

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters